Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genomic Health Inc (GHDX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 979,260
  • Shares Outstanding, K 33,380
  • Annual Sales, $ 287,460 K
  • Annual Income, $ -33,310 K
  • 36-Month Beta 0.51
  • Price/Sales 3.06
  • Price/Book 6.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.78 +0.76%
on 01/18/17
31.21 -10.32%
on 12/19/16
-2.99 (-9.65%)
since 12/16/16
3-Month
27.78 +0.76%
on 01/18/17
33.96 -17.58%
on 11/14/16
-1.83 (-6.14%)
since 10/18/16
52-Week
22.00 +27.23%
on 03/17/16
33.96 -17.58%
on 11/14/16
-1.65 (-5.57%)
since 01/15/16

Most Recent Stories

More News
The Top 100 U.S. In-Vitro Diagnostics Companies

Did you know?

MetaStat Presents Positive Data from Two Clinical Studies of MetaSite Breast(TM) at 2016 San Antonio Breast Cancer Symposium

--The assay provides complimentary prognostic information to Genomic Health's Oncotype DX gene panel to further guide treatment decisions for Patients with low Recurrence Scores

Genomic Health Posts Impressive Data for Oncotype DX Test

Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.

Will Endopredict Win Myriad's (MYGN) Genomic Testing War?

Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.

Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World

Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for...

Genomic Health: Cancer Test Business Strong, Q3 Dismal

On Dec 6, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine

Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10,...

Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference

Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale,...

Genomic Health (GHDX) Posts Wider-than-Expected Q3 Loss

Genomic Health (GHDX) reported third-quarter 2016 loss per share of 8 cents, an improvement from the year-ago quarter's loss figure of 36 cents. However, the loss figure was wider than the Zacks Consensus...

Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results

Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Support & Resistance

2nd Resistance Point 28.73
1st Resistance Point 28.36
Last Price 27.99
1st Support Level 27.70
2nd Support Level 27.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.